1017240-34-4

Basic information

• Product Name: 3-Biphenyl-4-yl-5-(4-chloro-phenyl)-4,5-dihydro-1H-pyrazole
• Synonyms: 3-Biphenyl-4-yl-5-(4-chloro-phenyl)-4,5-dihydro-1H-pyrazole
• CAS NO: 1017240-34-4
• Molecular Weight: 332.832
• Mol File: 1017240-34-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-Biphenyl-4-yl-5-(4-chloro-phenyl)-4,5-dihydro-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Biphenyl-4-yl-5-(4-chloro-phenyl)-4,5-dihydro-1H-pyrazole(1017240-34-4)
• EPA Substance Registry System: 3-Biphenyl-4-yl-5-(4-chloro-phenyl)-4,5-dihydro-1H-pyrazole(1017240-34-4)

Safety Data

• Hazardous Substances Data: 1017240-34-4(Hazardous Substances Data)

Upstream product

• 13662-60-7 4-Chloro-4'-phenylchalcone 
• 132434-50-5 (E)-1-([1,1'-biphenyl]-4-yl)-3-(4-chlorophenyl)prop-2-en-1-one 
• 92-91-1 biphenyl-4-acetaldehyde 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 1017240-42-4 C₂₈H₂₁ClN₂O 
• 77153-38-9 (cis)-1-p-Biphenylyl-2-(p-chlorophenyl)cyclopropane 
• 77153-39-0 (trans)-1-p-biphenylyl-2-(p-chlorophenyl)cyclopropane 

Relevant articles and documents

SAR studies of differently functionalized 4′-phenylchalcone based compounds as inhibitors of cathepsins B, H and L

Conditions related to the elevated levels of cathepsin B [3.4.22.1], cathepsin H [3.4.22.16] and cathepsin L [3.4.22.15] in various cancerous, rheumatoid arthritis and tissue degenerative disorders motivate the design, synthesis and evaluation of compound

Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents

A series of 3-(4-biphenyl)-5-substituted phenyl-2-pyrazolines (2a-h) and 1-benzoyl-3-(4-biphenyl)-5-substituted phenyl-2-pyrazolines (3a-h) were synthesized by condensation of chalcones with hydrazine hydrate in solvent system ethanol and DMF. The newly synthesized compounds were screened for their anti-inflammatory and analgesic activity, and were compared with standard drug. Among the compounds studied, compound 2e showed more potent anti-inflammatory and analgesic activity than the standard drug, along with minimum ulcerogenic index.